



HMDS, Bexley Wing, St. James's University Hospital, Leeds, LS9 7TF. Tel 0113 2067851

People at high risk of severe illness from COVID-19

Some individuals who are immunosuppressed due to underlying health conditions or medical treatment may not mount a full immune response to primary COVID-19 vaccination. The Joint Committee on Vaccination and Immunisation (JCVI) recommends that a third dose is given for individuals aged 12 and over with immunosuppression (see the Green Book Chapter 14a). This includes individuals under follow up for a chronic lymphoproliferative disorder including haematological malignancies such as indolent lymphoma, chronic lymphoid leukaemia, myeloma, Waldenstrom's macroglobulinemia and other plasma cell dyscrasias. This group will also require a reinforcing dose (booster) that should be offered from three months after the third dose. Those who have not yet received their third dose may be given their third dose now to avoid further delay. The table below lists diagnoses that are monitored through the Outreach service and meet the JCVI criteria. The diagnostic category is shown in large bold letters in the top right box on the Outreach report. A copy of this page and your most recent Outreach report should be sufficient to arrange the vaccination but please let us know if you need additional information.

Patients in the 'highest' risk groups should be contacted by NHS England (via letter or email) to advise them that if they become positive for COVID-19, confirmed by a PCR test, they may be eligible for non-hospitalised neutralising monoclonal antibody or antiviral treatment. If you have not received an alert from NHS England about this, and you have a diagnosis classed as highest risk in the list below, please pass this information to your GP. We will be happy to provide additional information if required.

Diagnostic categories eligible for 3rd primary COVID vaccine and booster (4th dose) 3 months later	Highest risk	ICDO3 CODE
B-cell chronic lymphocytic leukaemia (B-cell CLL)	Yes	9823/3
B-cell CLL - minimal residual disease present	Yes	9823/3
B-cell CLL post-treatment monitoring	Yes	9823/3
B-cell LPD NOS	Yes	9823/3
CD5+ LPD - intermediate phenotype	Yes	9823/3
CD5+/CD23- LPD NOS	Yes	9823/3
CD5-negative B-cell LPD NOS	Yes	9591/3
Chronic myeloid leukaemia - major molecular response		9875/3
Chronic myeloid leukaemia - outreach monitoring		9875/3
Chronic myeloid leukaemia - treated		9875/3
Hairy cell leukaemia	Yes	9940/3
Hairy cell leukaemia - variant	Yes	9940/3
HCL - residual disease detected	Yes	9940/3
IgM MGUS		9761/1
Monoclonal B-cell lymphocytosis (CLL phenotype)	*	9823/3
Monoclonal gammopathy of undetermined significance (MGUS)		9765/1
MYD88 mutated B-cell lymphoproliferative disorder	Yes	9689/3
Systemic marginal zone lymphoma	Yes	9689/3
T cell LGL leukaemia		9831/3
T-cell or NK cell large granular lymphocytosis		9831/3
WM post-treatment monitoring	Yes	9689/3

* may be eligible for non-hospitalised treatment in some cases, please contact HMDS to confirm